Health ❯Pharmaceuticals ❯Drug Discovery ❯Antibiotics
Chapter 7 liquidation of its Delaware subsidiaries clears capital for a planned August NDA filing for Zaynich in support of Wockhardt’s shift toward higher-margin research-led pharmaceuticals.
